PolyPeptide Group AG (SWX:PPGN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.33B +72.9% |
| Revenue (ttm) | 423.58M +24.4% |
| Net Income | 13.34M |
| EPS | 0.41 |
| Shares Out | 33.02M |
| PE Ratio | 98.68 |
| Forward PE | 37.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 409 |
| Open | 40.35 |
| Previous Close | 40.40 |
| Day's Range | 40.35 - 40.35 |
| 52-Week Range | 21.80 - 50.10 |
| Beta | 1.04 |
| Analysts | Hold |
| Price Target | 42.36 (+4.98%) |
| Earnings Date | Mar 9, 2027 |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ... [Read more]
Full Company ProfileFinancial Performance
In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PPGN stock is "Hold." The 12-month stock price target is CHF 42.36, which is an increase of 4.98% from the latest price.
News
PolyPeptide downgraded to Neutral from Buy at UBS
UBS downgraded PolyPeptide (PLYGF) to Neutral from Buy with a price target of CHF 44, down from CHF 45, after aligning the firm’s target with Samsung Biologics’ all-cash tender offer.
PolyPeptide downgraded to Hold from Buy at Berenberg
Berenberg analyst Estelle Betrisey downgraded PolyPeptide (PLYGF) to Hold from Buy with a price target of CHF 44, up from CHF 38. The firm recommends taking profits following the stock’s…
PolyPeptide downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded PolyPeptide (PLYGF) to Equal Weight from Overweight with a price target of CHF 44.31, up from CHF 40. The firm cites the expected end of Augusts prospectus release…
PolyPeptide Group AG Earnings Call Transcript: H1 2026
Revenue grew 41.6% year-over-year in H1 2026, with EBITDA margin rising to 20.7% and metabolics driving 73% growth. Upgraded guidance targets 25%-30% revenue growth and high-teens EBITDA margin for 2026. Samsung Biologics' acquisition offer at a significant premium is supported by the board and anchor shareholder.
PolyPeptide Group AG Earnings release: H1 2026
PolyPeptide Group AG released its H1 2026 earnings on August 13, 2026, summarizing the period's financial results.
PolyPeptide Group AG Quarterly report: H1 2026
PolyPeptide Group AG has published its H1 2026 quarterly earnings report on August 13, 2026.
PolyPeptide Group AG Slides: H1 2026
PolyPeptide Group AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 13, 2026.
PolyPeptide downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded PolyPeptide (PLYGF) to Sector Perform from Outperform with a CHF 44 price target Polypeptide shares have surged beyond the firm’s price target and towards the upper end…
PolyPeptide price target raised to CHF 38 from CHF 35 at Berenberg
Berenberg analyst Estelle Betrisey raised the firm’s price target on PolyPeptide (PLYGF) to CHF 38 from CHF 35 and keeps a Buy rating on the shares.
PolyPeptide price target raised to CHF 40 from CHF 33 at Barclays
Barclays raised the firm’s price target on PolyPeptide (PLYGF) to CHF 40 from CHF 33 and keeps an Overweight rating on the shares.
PolyPeptide is attracting takeover interest from EQT, KKR, Bloomberg says
PolyPeptide (PLYGF) Group is attracting private equity takeover interest, with EQT (EQBBF), KKR (KKR), and Advent among suitors looking into a potential acquisition of the company, Dinesh Nair, Allegr...
PolyPeptide Group AG Earnings Call Transcript: H2 2025
2025 saw 16% revenue growth and a sharp EBITDA margin improvement, driven by metabolic therapeutics and capacity expansions. 2026 guidance targets 20%-25% revenue growth and mid to high teens EBITDA margin, with strong customer prepayments and no equity raise planned.
PolyPeptide Group AG Earnings release: H2 2025
PolyPeptide Group AG released its H2 2025 earnings on March 12, 2026, summarizing the period's financial results.
PolyPeptide Group AG Annual report: H2 2025
PolyPeptide Group AG has published its H2 2025 annual report on March 12, 2026.
PolyPeptide Group AG Slides: H2 2025
PolyPeptide Group AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 12, 2026.
PolyPeptide price target lowered to CHF 33 from CHF 35 at Barclays
Barclays lowered the firm’s price target on PolyPeptide (PLYGF) to CHF 33 from CHF 35 and keeps an Overweight rating on the shares.